Erdogan-Trinkaus Ipek sold 1,160 shares of Eton Pharmaceuticals, Inc. at $67.88 for −$78.7k on Nov 10, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Commercial Officer
Chief Commercial Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$78,739.06Shares × reported price
Shares traded
1,160Common Stock
Price per share
$67.88Reported price. Read footnotes for ranges.
% of reported position traded
22.13%This security and ownership context
Holdings after
4,081Direct
Trade date
Nov 10, 2026Sell
Filed
Nov 12, 2026, 4:45 PM ET2-day reporting delay
Accession
0001437749-26-036605Code S · Transaction 399225
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 5,241 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 10, 2026Option exercise3,500$0.00$0Trade 399226
Nov 10, 2026Option exercise3,500$15.47$54,145Trade 399223
Nov 10, 2026Sell2,340$67.18−$157,198.16Trade 399224
4 transaction rows in this filing. Joint filers share the same rows.

ETON price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ETON · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −10%1w ago −17%1d ago −17%
Returns since7d30d90d180d1y

Footnotes in full

F1: The shares subject to the option vest in 48 equal monthly installments from the date of grant (1-12-2026) until fully vested and exercisable on January 12, 2030. F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F3: The shares were sold in multiple trades at prices ranging from $66.645 to $67.62. The price reported above reflects the weighted average sales price. F4: The shares were sold in multiple trades at prices ranging from $67.6825 to $68.075. The price reported above reflects the weighted average sales price.